Pre-therapeutic Microglia Activation and Sex Determine Therapy Effects of Chronic Immunomodulation
Abstract Modulation of the innate immune system is emerging as a promising therapeutic strategy against Alzheimer’s disease (AD). However, determinants of a beneficial therapeutic effect are ill-understood. Thus, we investigated the potential of 18 kDa translocator protein positron-emission-tomography (TSPO-PET) for assessment of microglial activation in mouse brain before and during chronic immunomodulation. Serial TSPO-PET was performed during five months of chronic microglia modulation by stimulation of peroxisome proliferator-activated receptor (PPAR)-γ with pioglitazone in two different mouse models of AD (PS2APP,AppNL-G-F). Using mixed statistical models on longitudinal TSPO-PET data, we tested for effects of therapy and sex on treatment response. We tested correlations of baseline with longitudinal measures of TSPO-PET, and correlations between PET results with spatial learning performance and β-amyloid accumulation of individual mice. Immunohistochemistry was used to determine the molecular source of the TSPO-PET signal. Pioglitazone-treated female PS2APP andAppNL-G-Fmice showed attenuation of the longitudinal increases in TSPO-PET signal when compared to vehicle controls, whereas treated maleAppNL-G-Fmice showed the opposite effect. Baseline TSPO-PET strongly predicted changes in microglial activation in treated mice (R=−0.874, p<0.0001) but not in vehicle controls (R=−0.356, p=0.081). Reduced TSPO-PET signal upon treatment was associated with better spatial learning and higher fibrillar β-amyloid accumulation. Immunohistochemistry confirmed activated microglia to be the source of the TSPO-PET signal (R=0.952, p<0.0001). TSPO-PET represents a sensitive biomarker for monitoring of immunomodulation and closely reflects activated microglia. Pre-therapeutic assessment of baseline microglial activation and sex are strong predictors of individual immunomodulation effects and could serve for responder stratification..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
bioRxiv.org - (2023) vom: 04. Nov. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Biechele, Gloria [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| doi: |
10.1101/2021.05.30.445761 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI031897703 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI031897703 | ||
| 003 | DE-627 | ||
| 005 | 20231105090706.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210602s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2021.05.30.445761 |2 doi | |
| 035 | |a (DE-627)XBI031897703 | ||
| 035 | |a (biorXiv)10.1101/2021.05.30.445761 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Biechele, Gloria |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pre-therapeutic Microglia Activation and Sex Determine Therapy Effects of Chronic Immunomodulation |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Modulation of the innate immune system is emerging as a promising therapeutic strategy against Alzheimer’s disease (AD). However, determinants of a beneficial therapeutic effect are ill-understood. Thus, we investigated the potential of 18 kDa translocator protein positron-emission-tomography (TSPO-PET) for assessment of microglial activation in mouse brain before and during chronic immunomodulation. Serial TSPO-PET was performed during five months of chronic microglia modulation by stimulation of peroxisome proliferator-activated receptor (PPAR)-γ with pioglitazone in two different mouse models of AD (PS2APP,AppNL-G-F). Using mixed statistical models on longitudinal TSPO-PET data, we tested for effects of therapy and sex on treatment response. We tested correlations of baseline with longitudinal measures of TSPO-PET, and correlations between PET results with spatial learning performance and β-amyloid accumulation of individual mice. Immunohistochemistry was used to determine the molecular source of the TSPO-PET signal. Pioglitazone-treated female PS2APP andAppNL-G-Fmice showed attenuation of the longitudinal increases in TSPO-PET signal when compared to vehicle controls, whereas treated maleAppNL-G-Fmice showed the opposite effect. Baseline TSPO-PET strongly predicted changes in microglial activation in treated mice (R=−0.874, p<0.0001) but not in vehicle controls (R=−0.356, p=0.081). Reduced TSPO-PET signal upon treatment was associated with better spatial learning and higher fibrillar β-amyloid accumulation. Immunohistochemistry confirmed activated microglia to be the source of the TSPO-PET signal (R=0.952, p<0.0001). TSPO-PET represents a sensitive biomarker for monitoring of immunomodulation and closely reflects activated microglia. Pre-therapeutic assessment of baseline microglial activation and sex are strong predictors of individual immunomodulation effects and could serve for responder stratification. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Blume, Tanja |4 aut | |
| 700 | 1 | |a Deussing, Maximilian |4 aut | |
| 700 | 1 | |a Zott, Benedikt |4 aut | |
| 700 | 1 | |a Shi, Yuan |4 aut | |
| 700 | 1 | |a Xiang, Xianyuan |4 aut | |
| 700 | 1 | |a Franzmeier, Nicolai |4 aut | |
| 700 | 1 | |a Kleinberger, Gernot |4 aut | |
| 700 | 1 | |a Peters, Finn |4 aut | |
| 700 | 1 | |a Ochs, Katharina |4 aut | |
| 700 | 1 | |a Focke, Carola |4 aut | |
| 700 | 1 | |a Sacher, Christian |4 aut | |
| 700 | 1 | |a Wind, Karin |4 aut | |
| 700 | 1 | |a Schmidt, Claudio |4 aut | |
| 700 | 1 | |a Lindner, Simon |4 aut | |
| 700 | 1 | |a Gildehaus, Franz-Josef |4 aut | |
| 700 | 1 | |a Eckenweber, Florian |4 aut | |
| 700 | 1 | |a Beyer, Leonie |4 aut | |
| 700 | 1 | |a von Ungern-Sternberg, Barbara |4 aut | |
| 700 | 1 | |a Bartenstein, Peter |4 aut | |
| 700 | 1 | |a Baumann, Karlheinz |4 aut | |
| 700 | 1 | |a Dorostkar, Mario M. |4 aut | |
| 700 | 1 | |a Rominger, Axel |4 aut | |
| 700 | 1 | |a Cumming, Paul |4 aut | |
| 700 | 1 | |a Willem, Michael |4 aut | |
| 700 | 1 | |a Adelsberger, Helmuth |4 aut | |
| 700 | 1 | |a Herms, Jochen |4 aut | |
| 700 | 1 | |a Brendel, Matthias |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2023) vom: 04. Nov. |
| 773 | 1 | 8 | |g year:2023 |g day:04 |g month:11 |
| 856 | 4 | 0 | |u https://doi.org/10.7150/thno.64022 |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2021.05.30.445761 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 04 |c 11 | ||